India’s DCGI, U.S. FDA Collaborate On Drug Rules
This article was originally published in PharmAsia News
The Drug Controller General of India and its U.S. counterpart, FDA, are in discussions expected to lead to a stronger regulatory agency. The talks cover improved monitoring of drugs, regulations covering medical devices and rules governing clinical practices and biologics. The DCGI also has plans to inspect plants in other countries, such as China, where raw materials are made for export to Indian drug makers. A DCGI team visited the FDA's offices last month and the U.S. agency plans to open offices in three Indian cities. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.